Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases, often associated with HLA-B27 that are characterized by axial inflammation, intestinal inflammation, inflammation at tendinous insertion points into joints, acute anterior uveitis, and psoriasis. Diseases included with SpA are axial spondyloarthritis, psoriatic arthritis, reactive arthritis, enteropathic arthritis/spondylitis associated with inflammatory bowel diseases, and undifferentiated spondyloarthritis, and in children, enthesitis related arthritis. The prevalence of SpA varies in different ethnic groups, from 0.2% in South-East Asia to 1.61% in Northern Arctic communities. The exact cause of SpA is still unclear, although genetics and environmental factors both play important roles.
Omics have emerged as great tools in genetic and pathogenesis research, biomarker discovery, disease diagnosis and disease treatment developing. Rapid progress in omics has shed light on understanding the disease etiology of SpA. Multiple genetic susceptibility loci have been identified, and the related pathways have been studied, including IL-17 and IL-23 pathways. Gut microbiota studies established a link between SpA and intestinal bacteria. Metabolomics studies have identified pathways such as those involving Tryptophan that are altered in SpA. This Research Topic aims to bring together recent advances on the application of omics in SpA and its related conditions to understand the mechanism of the disease, to identify diagnostic, predictive and pharmacodynamic/response biomarkers, and to develop methods for diagnosis or selection of therapeutic intervention.
We welcome the submission of Original Research, Systematic Review, Methods, Mini Review and Perspective articles, with potential topics including, but not limited to:
• Identification of genetic and epigenetic variants in SpA
• Fine mapping of the causal variants and genes in SpA
• Investigation of the interaction between environmental factors (e.g., bacteria) and genetic factors in SpA
• Investigation of potential biomarkers of SpA through omics methods
• Advance methods using omics data to facilitate diagnosis, prevention or therapeutic intervention in SpA
Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases, often associated with HLA-B27 that are characterized by axial inflammation, intestinal inflammation, inflammation at tendinous insertion points into joints, acute anterior uveitis, and psoriasis. Diseases included with SpA are axial spondyloarthritis, psoriatic arthritis, reactive arthritis, enteropathic arthritis/spondylitis associated with inflammatory bowel diseases, and undifferentiated spondyloarthritis, and in children, enthesitis related arthritis. The prevalence of SpA varies in different ethnic groups, from 0.2% in South-East Asia to 1.61% in Northern Arctic communities. The exact cause of SpA is still unclear, although genetics and environmental factors both play important roles.
Omics have emerged as great tools in genetic and pathogenesis research, biomarker discovery, disease diagnosis and disease treatment developing. Rapid progress in omics has shed light on understanding the disease etiology of SpA. Multiple genetic susceptibility loci have been identified, and the related pathways have been studied, including IL-17 and IL-23 pathways. Gut microbiota studies established a link between SpA and intestinal bacteria. Metabolomics studies have identified pathways such as those involving Tryptophan that are altered in SpA. This Research Topic aims to bring together recent advances on the application of omics in SpA and its related conditions to understand the mechanism of the disease, to identify diagnostic, predictive and pharmacodynamic/response biomarkers, and to develop methods for diagnosis or selection of therapeutic intervention.
We welcome the submission of Original Research, Systematic Review, Methods, Mini Review and Perspective articles, with potential topics including, but not limited to:
• Identification of genetic and epigenetic variants in SpA
• Fine mapping of the causal variants and genes in SpA
• Investigation of the interaction between environmental factors (e.g., bacteria) and genetic factors in SpA
• Investigation of potential biomarkers of SpA through omics methods
• Advance methods using omics data to facilitate diagnosis, prevention or therapeutic intervention in SpA